Lv1
60 积分 2024-10-02 加入
Engineered natural killer cells for cancer therapy
4个月前
已完结
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
5个月前
已完结
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
5个月前
已完结
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
5个月前
已完结
Triple knockdown of CD11a , CD49d , and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice
5个月前
已完结
Neurological complications of CAR T cell therapy for cancers
5个月前
已完结
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
5个月前
已完结
CAR-T therapy in solid tumors
8个月前
已完结
皖公网安备34019202002308
